Psychotropics in Pulmonary Disease

Psychopharmacology in Medical Conditions · Rapid Decision Guide

Psychotropics in Pulmonary Disease

Psychotropics in Pulmonary Disease — Rapid Decision Guide

Your patient has no respiratory reserve, or they smoke — and either fact quietly changes what every psychotropic on their list is doing. This course is the point-of-care guide to both.

Prescribing psychotropics in lung disease turns on two questions that the usual references bury. Does this drug depress a respiratory system that has no margin to spare? And is a CYP1A2 substrate’s level about to swing because the patient’s smoking is about to change? Miss either and the consequences are real — an over-sedated retainer, or a clozapine level that climbs into toxicity the week a patient finally quits.

Across fourteen chapters, this guide works through the antidepressants, antipsychotics, mood stabilizers, and anxiolytics against COPD, sleep apnea, the hypercapnic retainer, smoking cessation, and end-of-life breathlessness — every figure verified against primary literature, every honest uncertainty named rather than smoothed over. It is built to be scanned at the bedside, not read like a textbook.

14Chapters
3Sections
2Free previews

The whole course, in two questions

Axis 1 — Respiratory reserve. Does this drug depress a system with no margin? No PaCO₂ number grants permission to sedate, and none forbids it — judge the drug, the dose, and the stack, not the gas.
Axis 2 — The smoking–CYP1A2 lever. Is a clozapine, olanzapine, or theophylline level about to move because the smoking changed? It’s the smoke, not the nicotine.

Start free — two chapters, no membership required

Free preview

Ch 1 · The Pulmonary Decision Framework

The three questions to ask before any psychotropic decision in a lung patient — reserve, the smoking lever, and the depressant stack — and the two axes the whole course is built on.

Read Chapter 1 →
Free preview

Ch 2 · The Smoking–CYP1A2 Lever

Why starting, stopping, or a forced hospital quit swings clozapine and olanzapine levels — the forced-quit toxicity trap, and why NRT and vaping don’t spare the enzyme.

Read Chapter 2 →

Chapters 3–14 are included with Academy membership. The full drug-class decisions, the safety anchors, the myths worth not believing, and the one-page rapid-reference capstone.

Get the complete Pulmonary Rapid Decision Guide

Unlock all fourteen chapters — and every other course in the Psychopharmacology in Medical Conditions series — with a single Academy membership.

Become a Member →

Part of the seven-course series — explore the full Rapid Decision Guide →

Responses

Your email address will not be published. Required fields are marked *